It is the mission of the Alliance to serve as an authoritative resource center for the public, medical community, the U.S. Food and Drug Administration and government regulators worldwide as biosimilars policies are developed and implemented.
Who We Are
The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups and individuals—from patients to physicians, biotechnology companies that develop innovative and biosimilar medicines and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion. Our membership list and steering committee reflect the wide range of voices within the healthcare community. Our coalition ultimately strives to position itself to be an authoritative resource center of information for the healthcare and policy communities.
- We believe patients have the right to expect the same quality in drugs, whether they get the originator product or a biosimilar, irrespective of price.
- We believe medical decisions ought to remain between a patient, his or her physician, and the other healthcare professionals from whom the patient receives direct care, not in the hands of third parties such as government payers, pharmacy benefit managers, or private insurers.”
- We believe that patients need full information about how biosimilars work in order to make informed choices.
- We believe that while the ultimate goal is to find a balance between producing economical drugs for our patients and respecting the drug-discovery process, we must never forget that patient safety is paramount.